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Abstract Toxic methemoglobinemia is an uncommon
blood disorder induced by exposure to certain oxidizing
agents and drugs. In severe cases, this condition may
rapidly lead to major cardiopulmonary compromise and
constitutes an emergency requiring prompt recognition and
early management. We report an unusual case of severe
toxic methemoglobinemia following wide cutaneous appli-
cation of a pomade containing benzocaine, resorcin, and
oxyquinoline (Nestosyl®) in an infant.
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Introduction
Methemoglobinemia is a rare blood disorder, characterized
by abnormal levels of oxidized hemoglobin that cannot
bind to and transport oxygen [1, 2]. The clinical picture is
characterized by acute cyanosis and low oxygen saturations
on pulse oximetry but normal oxygen saturation on arterial
blood gas analysis [1]. When untreated, methemoglobine-
mia can lead to major cardiopulmonary compromise,
neurologic sequela, and even death [2]. Thus, knowledge
of this potentially life-threatening condition is essential for
clinicians. This report describes an original case of toxic
methemoglobinemia induced by wide cutaneous application
of a pomade containing benzocaine, resorcin, and quinoline
(Nestosyl®) in a 16-month-old boy. To our knowledge, this
cause and route of intoxication has not been previously
reported in the literature.
Case report
A previously healthy 16-month-old boy presented to our
emergency department for sudden development of cyano-
sis. On physical examination, the infant was agitated and
unconscious (Glasgow Coma Scale=12/15), with a 38°C
fever, a low oxygen saturation of 76%, under 3 l/min of
oxygen through nasal cannulae. His hemodynamic state was
unstable with a heart rate of 200 bpm, a prolonged capillary
refill time, and weak pulses. Besides, the patient presented
widespread lesions of molluscum contagiosum on the anterior
face of the thorax and the limbs. The infant was immediately
intubated and mechanically ventilated with vascular filling
(20ml/kgofnormalsaline0.9%).Thecyanosiswasrefractory
to oxygen (FiO2=1). The chest radiograph was normal and
particularly eliminated a pulmonary barotrauma. The echo-
cardiogram was normal. An arterial blood gas analysis
revealed pH: 7.57, PaO2: 157.4 mmHg, PCO2:1 2 . 5m m H g ,
HCO3
−: 11.6 mmol/l, oxygen saturation (SatO2): 99.7%, and
a methemoglobin level at 50.6% of total hemoglobin.
Treatment of methemoglobinemia was then instituted using
a methylene blue 1% solution (10 mg/ml) with a loading
dose of 2 mg/kg administered intravenously over 5 min
followed by 1 mg/kg twice daily. The parents were
questioned about the different drugs and chemicals received
recently by the infant. We found then the notion of
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with wide cutaneous application on the lesions of mollus-
cum contagiosum and consumption of about half of a tube.
After ruling out the other acquired causes of methemoglo-
binemia, and with a high degree of suspicion, methemo-
globinemia was considered to be secondary to the wide
cutaneous application of this pomade containing three
components causing this complication: benzocaine, resor-
cin, and 8-hydroxyquinoline. Under methylene blue therapy
and mechanical ventilation, the clinical course was favor-
able with rapid improvement of cyanosis, neurologic status,
and hemodynamic state. Twenty-four hours later, methe-
moglobin levels decreased to 9.8%. The patient was
weaned from mechanical ventilation on day 2 and dis-
charged on day 3 of his admission to the pediatric intensive
care unit.
Comments
Methemoglobin is formed when the iron in hemoglobin is
oxidized from ferrous (Fe
2+) to ferric (Fe
3+) state. Once
formed, the molecule loses its ability to bind oxygen and
also interferes with oxygen delivery to the tissues. The
diagnosis of methemoglobinemia should be suspected in
any patient with unexplained cyanosis and discordance
between low oxygen saturation on pulse oximetry and
normal blood gas concentrations of oxygen. The measure-
ment of methemoglobin levels on arterial blood sampling is
necessary to confirm the diagnosis [1]. Patients may appear
cyanotic when their methemoglobin level exceeds 15% and
generally become symptomatic when this level exceeds
30%. Common symptoms are anxiety, dizziness, headache,
tachycardia, arrhythmias, and confusion. When the level of
methemoglobin exceeds 50%, dyspnea, acidosis, heart
failure, seizures, coma, and death can occur [1]. Our patient
had a high level of methemoglobin above 50% explaining
the severity of his clinical presentation. However, the
clinical course was favorable under treatment. In fact,
treatment of toxic methemoglobinemia is effective, if
started promptly, and includes oxygenotherapy, discontinua-
tion of causative medications, and intravenous administration
of the antidote methylene blue [1, 2]. Methemoglobinemia
can be acquired, induced by exposure to certain oxidizing
agents and drugs, or hereditary, related to deficiency of one
of the enzymes necessary for reduction of methemoglobin to
hemoglobin or to the presence of an abnormal hemoglobin
resistant to reduction [2]. In our case, toxic methemoglobi-
nemia was induced by wide cutaneous application of
Nestosyl® pomade. This drug is a local antipruritic indicated
for the symptomatic treatment of insects’ bites. It is an over-
the-counter medication but its use is prohibited in children
under the age of 12 years. Its application on wide cutaneous
surfaces and on deep cutaneous lesions is also prohibited.
Nestosyl® contains butoform, benzocaine, resorcin, and 8-
hydroxyquinoline: the latter three can induce methemoglo-
binemia [3]. After review of the literature, we found only one
case of methemoglobinemia induced by Nestosyl® after
accidental ingestion [3] and five cases of methemoglobine-
mia induced by the association of two or three of these
components [3–7]. Benzocaine is a local anesthetic com-
monly used for a variety of invasive procedures and
constitutes the main component in a wide variety of creams
and gels used for analgesia and anesthesia [8]. Since the first
reported case of benzocaine-induced methemoglobinemia in
1950, there have been approximately 95 cases reported in the
literature [2, 8–11]. Resorcin and 8-hydroxyquinoline are a
part of the composition of several drugs because of their
antiseptic effects. They were less frequently incriminated in
cases of methemoglobinemia than benzocaine [3–7, 12].
Occurrence of methemoglobinemia via a transcutaneous
route is also uncommon. Approximately six cases have been
reported in the literature. The majority of them were induced
by a eutectic mixture of local anesthetics (EMLA) cream and
occurred in newborns and infants [13–15]. In our case, the
automedication by Nestosyl® with unawareness of the
potential risks and the limitations of use of this treatment
caused methemoglobinemia: a potentially life-threatening
complication. Thus, it is important to recognize possible drug
reactions and to educate parents about the potential risks of
treatment with over-the-counter medications, especially in
neonates and infants [3].
Conclusion
This report illustrates an original case of toxic methemo-
globinemia occurring in a 16-month-old infant after wide
cutaneous application of a pomade containing benzocaine,
resorcin, and hydroxyquinoline and demonstrates the
possibility of the occurrence of severe systemic effects of
drugs after wide cutaneous application especially in neo-
nates and infants. It is thus important to educate parents
about the potential risks of dermatological treatments,
especially in young children.
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